Acquisition of the cardiovascular business

0

The final agreement for the acquisition of clevidipine injectable emulsion, cangrelor and argatroban for injection has been signed between The Medicines Company and Chiesi Farmaceutici. The total value of the deal is $792 million. The three cardiovascular products are intended for use in the hospital setting and are approved for sale in the U.S. The transaction is expected to close in the third quarter of 2016 and, according to Chiesi, it is aimed to expand the product portfolioof the Italian multinational in the US to become a recognized leader in the hospital and adjacent specialties.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here